Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 30:1351–1356, 2007

In Table 2 of the above-listed article, column headings for “Telmisartan” and “Ramipril” were incorrectly placed. The correct table appears below.

Table 2—

Effects of 80 mg telmisartan and 10 mg ramipril on secondary renal end points and MAP

Parameter*Telmisartan
Ramipril
Before treatmentAfter treatmentP valueBefore treatmentAfter treatmentP value
RPF (ml/min) 652 ± 27.0 696 ± 31.0 0.047 631 ± 27.3 658 ± 28.2 0.221 
GFR (ml/min) 136.3 ± 3.1 136.4 ± 3.4 0.212 134.3 ± 3.7 133.7 ± 3.8 0.558 
Filtration fraction (%) 22.0 ± 0.8 20.6 ± 0.7 0.020 22.2 ± 0.7 21.4 ± 0.7 0.154 
MAP (mmHg) 100.0 ± 10.4 93.3 ± 10.8 <0.001 100.1 ± 9.2 95.4 ± 11.0 0.009 
Renal vascular resistance (RU) 96.2 ± 4.2 87.1 ± 4.2 0.010 99.3 ± 4.7 93.7 ± 5.1 0.119 
Parameter*Telmisartan
Ramipril
Before treatmentAfter treatmentP valueBefore treatmentAfter treatmentP value
RPF (ml/min) 652 ± 27.0 696 ± 31.0 0.047 631 ± 27.3 658 ± 28.2 0.221 
GFR (ml/min) 136.3 ± 3.1 136.4 ± 3.4 0.212 134.3 ± 3.7 133.7 ± 3.8 0.558 
Filtration fraction (%) 22.0 ± 0.8 20.6 ± 0.7 0.020 22.2 ± 0.7 21.4 ± 0.7 0.154 
MAP (mmHg) 100.0 ± 10.4 93.3 ± 10.8 <0.001 100.1 ± 9.2 95.4 ± 11.0 0.009 
Renal vascular resistance (RU) 96.2 ± 4.2 87.1 ± 4.2 0.010 99.3 ± 4.7 93.7 ± 5.1 0.119 

Data are means ± SE.

*

No significant differences in the changes due to treatment were observed between telmisartan and ramipril. RU, resistance unit.

View Large
View Original Article
DIABETES CARE
2007